Asalyxa Bio

What Asalyxa Bio does

Asalyxa Bio is a privately held, preclinical-stage biotechnology company founded in 2020 and headquartered in Southfield, Michigan. The company is focused on developing therapeutics that target neutrophils — the most abundant class of white blood cells and central effectors of inflammatory and innate immune responses — for application in diseases characterized by high unmet medical need. According to available firmographic data, the company employs between 11 and 50 people and operates as a for-profit entity with no public-market listing. The technology platform is positioned as a neutrophil-targeting drug delivery or modulation approach, but the available input contains no detailed description of the underlying scientific mechanism, specific product candidates, target indications, development stage, or intellectual property estate (no patents or trademarks were disclosed).

The company is led by a four-person executive team composed of co-founder and CSO Lola Eniola-Adefeso — whose background appears rooted in biomedical engineering research — alongside co-founder and CEO Marc Appel, Chief Operating Officer Ryan Fox, and Head of Corporate Development John Freshley. This composition is consistent with an early-stage biotech balancing scientific leadership with operational and business development capacity. There are no disclosed clinical trial programs, partnerships, licensing deals, or commercial products in the source data, and the company's revenue model is not articulated. Asalyxa Bio's only documented capital event is a $2,000,000 seed funding round closed on February 23, 2021, led by Research Bridge Partners with participation from Ann Arbor SPARK, Biosciences Research and Commercialization Center (BRCC), Invest Detroit Ventures, LoftyInc Capital, Michigan Rise, and Woodward Angels. As is typical for early-stage biotech, the implied business model is venture-funded R&D with eventual value realization through outlicensing, partnership, acquisition, or independent commercialization — none of which have materialized in the available data.

A material operational discontinuity is evident: the company's primary web domain, Asalyxabio.com, is currently listed for sale on the HugeDomains marketplace for $5,295 (or $220.63/month over 24 months). This is a negative signal that warrants further diligence — it could indicate domain expiry and loss, corporate wind-down, rebranding to an alternate domain, or simply divestiture of a non-essential digital asset — but the source material does not resolve which. Combined with the absence of any post-2021 funding, pipeline, or partnership disclosures, the available evidence points to limited observable forward momentum since the seed round, though the company's underlying operating status cannot be definitively determined from the inputs provided.

Name

Asalyxa Bio

Legal name

Asalyxa Bio

Website

https://asalyxabio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Asalyxa Bio is a preclinical-stage, privately held biotech founded in 2020 in Southfield, Michigan, developing neutrophil-targeting therapeutics for diseases with high unmet medical need. The company is venture-funded and has no commercial products or disclosed revenue.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Neutrophil therapeutics
• Drug development
• Inflammatory disease treatments
• Biopharmaceutical research
• Targeted drug delivery

Headquarters

HQ city

Southfield

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Asalyxa Bio is an early-stage biopharmaceutical company developing neutrophil-targeting therapeutics aimed at treating diseases with a high unmet medical need. The company's core scientific focus is on engineering drug delivery approaches that leverage neutrophils as a therapeutic vehicle or target for hard-to-treat conditions.

Product overview

No product or service information is available. The source data consists solely of a domain marketplace listing (HugeDomains) showing that the domain AsalyxaBio.com is for sale for $5,295. The actual company Asalyxa Bio does not appear to have an operational website or documented product offerings in the available source material.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights2 records

Emerging players

• Prometheus Biosciences: Prometheus Biosciences (acquired by Merck in 2023) developed precision immunology therapeutics for immune-mediated diseases. Comparable as a focused immunology biotech with overlapping therapeutic area.
• Cartesian Therapeutics: Cartesian Therapeutics (formerly Selecta Biosciences) develops engineered cell and nanoparticle immunomodulatory therapies for autoimmune and inflammatory disease. Comparable as a small-cap immunology platform company.
• Provention Bio: Provention Bio (acquired by Sanofi in 2023) developed therapeutics for autoimmune and inflammatory diseases. Comparable as a clinical-stage immunology company with similar indication focus.
• Inflammatix: Inflammatix develops host-response diagnostics and immunomodulatory therapeutics aimed at dysregulated immune responses in acute and chronic inflammation. Comparable as an emerging immunology-focused company with overlapping therapeutic interests.
• Arcturus Therapeutics: Arcturus is a clinical-stage mRNA and delivery-technology company developing therapeutics for rare and inflammatory diseases. Comparable as an emerging platform biotech working on novel immune-cell-directed delivery approaches.

Direct peers

• CytoAgents: CytoAgents is a clinical-stage biotech developing neutrophil-targeted therapeutics for inflammatory conditions. It is the closest functional peer to Asalyxa Bio given its focus on modulating neutrophil-driven inflammation.
• XBiotech: XBiotech develops monoclonal antibody therapeutics targeting inflammation and immune-mediated disease, including indications involving neutrophil biology. Comparable as a small-cap inflammation biotech with a biologic pipeline.

Broad incumbents

• Eli Lilly: Eli Lilly has a major immunology portfolio (Taltz, Olumiant) and active R&D in neutrophil-driven autoimmune disease. Comparable as a broad incumbent operating in the same therapeutic category.
• AbCellera: AbCellera operates an antibody discovery platform that partners with pharma to develop biologic therapeutics, including immunology programs. Comparable at the biologic-platform level, though at meaningfully greater scale and capitalization.
• AbbVie: AbbVie operates one of the largest immunology franchises (Humira, Skyrizi, Rinvoq) addressing inflammatory conditions involving neutrophil biology. Comparable as a broad incumbent that dominates the same therapeutic space.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/asalyxabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asalyxa Bio